Product Description
Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Chiron
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Hong Kong, Israel, Korea, New Zealand, United States
Active Clinical Trial Count: 16
Highest Development Phases
Phase 2: Acute Myeloid Leukemia|Adenocarcinoma|Alzheimer Disease|Bipolar Disorder|Bladder Cancer|COVID-19|Carcinoma, Adenosquamous|Cholangiocarcinoma|Chronic Myeloid Leukemia|Colorectal Cancer|Conjunctivitis, Allergic|Digestive System Cancer|Endometrial Cancer|Esophageal Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Kidney Cancer|Melanoma|Neuroblastoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Rhinitis, Allergic, Seasonal|Soft Tissue Cancer|Squamous Cell Carcinoma|Synovial Sarcoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Type 1 Diabetes
Phase 1: Breast Cancer|Cervical Cancer|Hepatitis B|Lung Cancer|Oncology Solid Tumor Unspecified|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 0752-20-HMO | P2 |
Recruiting |
Soft Tissue Cancer|Transitional Cell Carcinoma|Bladder Cancer|Melanoma|Ovarian Cancer|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Neuroblastoma|Synovial Sarcoma |
2027-12-30 |
|
| Pro2022002198 | P1 |
Recruiting |
Lung Cancer|Gastrointestinal Cancer|Breast Cancer|Uterine Cancer|Cervical Cancer |
2026-09-01 |
|
| Study of LN 145 in patients with Metastatic Non-Small-Cell Lung Cancer | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2026-05-05 |
|
| IL-2-AD | P2 |
Recruiting |
Alzheimer Disease |
2025-09-01 |